Jeannette Potts Biography and Net Worth

Insider of uniQure

Dr. Jeannette Potts joined uniQure as our Chief Legal and Compliance Officer in May 2023. Dr. Potts has more than 25 years of global legal, management and transactional experience in the biopharmaceutical industry. Most recently, she served as Senior Vice President, General Counsel & Corporate Secretary at Forma Therapeutics, a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancer, which was acquired by Novo Nordisk in 2022. There she designed, built and led the legal/IP/compliance team, held key roles in corporate financings and business development transactions, and was a trusted advisor to the executive team and Board of Directors on complex legal and business matters.

Prior to joining Forma, Dr. Potts served as Vice President, Legal and Head Counsel, Research and Development, at Takeda Pharmaceuticals, and had previously been Vice President, Legal at Millennium Pharmaceuticals before it was acquired by Takeda. She holds a bachelor’s degree in biology from Smith College, a Ph.D. in anatomy and cell biology from the University of Virginia, and a J.D. from Suffolk University.

What is Jeannette Potts' net worth?: The estimated net worth of Jeannette Potts is at least $1.34 million as of June 13th, 2024. Potts owns 91,819 shares of uniQure stock worth more than $1,335,048 as of May 1st. This net worth estimate does not reflect any other investments that Potts may own. Learn More about Jeannette Potts' net worth.
How do I contact Jeannette Potts?: The corporate mailing address for Potts and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Jeannette Potts' contact information.
Has Jeannette Potts been buying or selling shares of uniQure?: Jeannette Potts has not been actively trading shares of uniQure during the last ninety days. Most recently, Jeannette Potts sold 4,781 shares of the business's stock in a transaction on Thursday, June 13th. The shares were sold at an average price of $4.98, for a transaction totalling $23,809.38. Following the completion of the sale, the insider now directly owns 91,819 shares of the company's stock, valued at $457,258.62. Learn More on Jeannette Potts' trading history.
Who are uniQure's active insiders?: uniQure's insider roster includes Walid Abi-Saab (Insider), Pierre Caloz (COO), Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Christian Klemt (CFO), Alexander Kuta, III (VP), and Jeannette Potts (Insider). Learn More on uniQure's active insiders.
Are insiders buying or selling shares of uniQure?: In the last twelve months, insiders at the biotechnology company sold shares 12 times. They sold a total of 104,493 shares worth more than $1,042,573.95. The most recent insider tranaction occured on March, 4th when CEO Matthew C Kapusta sold 28,341 shares worth more than $291,628.89. Insiders at uniQure own 4.7% of the company. Learn More about insider trades at uniQure.
Information on this page was last updated on 3/4/2025.

Jeannette Potts Insider Trading History at uniQure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/13/2024	Sell	4,781	$4.98	$23,809.38	91,819

Jeannette Potts Buying and Selling Activity at uniQure

uniQure Company Overview

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Today's Range

Now: $14.54

$14.95

50 Day Range

MA: $12.00

$8.34

$14.77

2 Week Range

Now: $14.54

$3.73

$19.18

Volume

5,959 shs

Average Volume

1,769,440 shs

Market Capitalization

$786.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42